AMGN · 8-K · 20260804PR000124
Guidance and Outlook
AMGEN INC · 2026-08-04 · Importance 69 · Surprise 60 · No source text
For the year ending December 31, 2026, Amgen reaffirmed GAAP diluted EPS guidance of $15.80 to $17.08 and non-GAAP diluted EPS guidance of $22.30 to $23.50. The non-GAAP range includes primarily acquisition-related amortization and acquired-inventory adjustments of $6.04 to $6.12 per share, plus $0.42 per share of net losses from equity investments. GAAP tax-rate guidance is 14.5% to 16.0%, while non-GAAP tax-rate guidance is 15.0% to 16.5%, reflecting a 0.5-percentage-point tax rate on known adjustments. The GAAP guidance excludes potential subsequent effects from acquisitions, asset impairments, litigation, contingent consideration revaluations, and equity-investment fair-value changes.
Key facts
- For the full year 2026, the Company expects Total revenues in the range of $38.2 billion to $39.4 billion. source
- For the full year 2026, on a GAAP basis, EPS is expected in the range of $15.80 to $17.08, and a tax rate in the range of 14.5% to 16.0%. source
- For the full year 2026, on a non-GAAP basis, EPS is expected in the range of $22.30 to $23.50, and a tax rate in the range of 15.0% to 16.5%. source
- Amgen's GAAP diluted EPS guidance for the year ending December 31, 2026 is a range of $15.80 to $17.08. source
- Amgen's non-GAAP diluted EPS guidance for the year ending December 31, 2026 is a range of $22.30 to $23.50. source
- Amgen's GAAP tax rate guidance for the year ending December 31, 2026 is a range of 14.5% to 16.0%. source
- Amgen's non-GAAP tax rate guidance for the year ending December 31, 2026 is a range of 15.0% to 16.5%. source
- Amgen's known acquisition-related expenses adjustment to arrive at non-GAAP diluted EPS guidance for the year ending December 31, 2026 is $6.04 to $6.12 per share. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | For the full year 2026, the Company expects Total revenues in the range of $38.2 billion to $39.4 billion. |
| net_income | unclear | committed | — | For the full year 2026, on a GAAP basis, EPS is expected in the range of $15.80 to $17.08, and a tax rate in the range of 14.5% to 16.0%. |
| net_income | unclear | committed | — | For the full year 2026, on a non-GAAP basis, EPS is expected in the range of $22.30 to $23.50, and a tax rate in the range of 15.0% to… |
| net_income | unclear | committed | — | Amgen's GAAP diluted EPS guidance for the year ending December 31, 2026 is a range of $15.80 to $17.08. |
| net_income | unclear | committed | — | Amgen's non-GAAP diluted EPS guidance for the year ending December 31, 2026 is a range of $22.30 to $23.50. |
| net_income | unclear | committed | — | Amgen's GAAP tax rate guidance for the year ending December 31, 2026 is a range of 14.5% to 16.0%. |
| net_income | unclear | committed | — | Amgen's non-GAAP tax rate guidance for the year ending December 31, 2026 is a range of 15.0% to 16.5%. |
| net_income | negative | committed | — | Amgen's known acquisition-related expenses adjustment to arrive at non-GAAP diluted EPS guidance for the year ending December 31, 2026 is… |
| net_income | negative | committed | — | Amgen's known net losses from equity investments adjustment to arrive at non-GAAP diluted EPS guidance for the year ending December 31,… |
| net_income | negative | committed | — | Amgen's other adjustment to arrive at non-GAAP diluted EPS guidance for the year ending December 31, 2026 is $(0.04) per share. |
| net_income | unclear | contingent | — | Amgen's GAAP diluted EPS guidance does not include effects of GAAP adjustments triggered by events after this press release such as… |